Anti-PLCG2 Antibody, clone 1L6 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (UniProt: P16885; also known as EC:3.1.4.11, Phosphoinositide phospholipase C-gamma-2, Phospholipase C-IV, PLC-IV, Phospholipase C-gamma-2, PLC-gamma-2) is encoded by the PLCG2 gene (Gene ID: 5336) in human. The gene encoding this protein is localized on human chromosome 16. PLCG2 is a crucial enzyme in the phosphoinositide signaling pathway, which regulates various cellular processes including proliferation, differentiation, and apoptosis. It catalyzes the conversion of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate to 1D-myo-inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) using calcium as a cofactor. IP3 and DAG are second messenger molecules important for transmitting signals from growth factor receptors and immune system receptors across the cell membrane. PLCG2 is a transmembrane multidomain protein which is expressed in mast cells and B cells. Its expression is predominantly observed in immune cells, particularly microglia, where it plays a pivotal role in the inflammatory response. Structurally, PLCG2 contains an N-terminal pleckstrin homology (PH) domain that binds to phosphoinositides, a central catalytic domain, and multiple SH2 domains that facilitate interactions with receptor tyrosine kinases and other signaling molecules. Mutations in this gene have been found in autoinflammation, antibody deficiency, and immune dysregulation syndrome and familial cold autoinflammatory syndrome 3. Dysregulation of PLCG2 has been linked to several diseases, including autoimmune disorders and Alzheimer′s disease (AD), where genetic variants of PLCG2 have been associated with altered microglial function and increased risk of neuroinflammation. Recent studies suggest that PLCG2 may serve as a potential therapeutic target in AD, given its involvement in microglial activation and the inflammatory response associated with amyloid plaques. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Tsai, A.P., et al. (2022). Genome Med. 18;14(1):17; Andreone, B.J., et al. (2020). Nat Neurosci. 23(8):927-938).

KLH-conjugated linear peptide corresponding to 17 amino acids from the C-terminal region of human PLCG2.

Quality Control Testing

Evaluated by Western Blotting in Daudi cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected PLCG2 in Daudi cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected PLCG2 in lysates from Ramos cells, RAW 264.7 cells and rat spleen tissue.

Affinity Binding Assay: A representative lot of this antibody bound PLCG2 peptide with at least ten million-fold (10,000,000X) higher affinity than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected PLCG2 in Daudi cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1L6 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects PLCG2. It targets an epitope within 17 amino acids from the C-terminal region.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.